BRPI0719835A2 - Enantiômero de cetoconazol em humanos - Google Patents

Enantiômero de cetoconazol em humanos

Info

Publication number
BRPI0719835A2
BRPI0719835A2 BRPI0719835-3A2A BRPI0719835A BRPI0719835A2 BR PI0719835 A2 BRPI0719835 A2 BR PI0719835A2 BR PI0719835 A BRPI0719835 A BR PI0719835A BR PI0719835 A2 BRPI0719835 A2 BR PI0719835A2
Authority
BR
Brazil
Prior art keywords
humans
ketoconazole enantiomer
ketoconazole
enantiomer
Prior art date
Application number
BRPI0719835-3A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Timothy Andrew Stewart
Original Assignee
Cortendo Invest Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortendo Invest Ab filed Critical Cortendo Invest Ab
Publication of BRPI0719835A2 publication Critical patent/BRPI0719835A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0719835-3A2A 2006-10-02 2007-10-02 Enantiômero de cetoconazol em humanos BRPI0719835A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84896306P 2006-10-02 2006-10-02
PCT/US2007/080186 WO2008042898A2 (en) 2006-10-02 2007-10-02 Ketoconazole enantiomer in humans

Publications (1)

Publication Number Publication Date
BRPI0719835A2 true BRPI0719835A2 (pt) 2014-05-06

Family

ID=39269161

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0719835-3A2A BRPI0719835A2 (pt) 2006-10-02 2007-10-02 Enantiômero de cetoconazol em humanos

Country Status (12)

Country Link
US (4) US9198906B2 (cg-RX-API-DMAC7.html)
EP (1) EP2076265A4 (cg-RX-API-DMAC7.html)
JP (1) JP2010505866A (cg-RX-API-DMAC7.html)
AU (1) AU2007303219A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0719835A2 (cg-RX-API-DMAC7.html)
CA (1) CA2664800A1 (cg-RX-API-DMAC7.html)
IL (1) IL197986A0 (cg-RX-API-DMAC7.html)
NO (1) NO20091593L (cg-RX-API-DMAC7.html)
NZ (1) NZ576569A (cg-RX-API-DMAC7.html)
RU (1) RU2009116632A (cg-RX-API-DMAC7.html)
WO (1) WO2008042898A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200902127B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090233843A1 (en) * 2005-01-10 2009-09-17 Cortendo Invest Ab Methods and compositions for treating diabetes, metabolic syndrome and other conditions
AU2007204969A1 (en) * 2006-01-10 2007-07-19 Cortendo Invest Ab Methods and compositions for treating prostate cancer
AU2007303219A1 (en) 2006-10-02 2008-04-10 Cortendo Ab (Publ) Ketoconazole enantiomer in humans
US20160244436A1 (en) * 2013-09-25 2016-08-25 Cortendo Ab (Publ) Novel functionalized 5-(phenoxymethyl)-1,3-dioxane analogs exhibiting cytochrome p450 inhibition and their method of use
WO2016048984A1 (en) * 2014-09-25 2016-03-31 Cortendo Ab (Publ) Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole
CN113710250A (zh) 2019-03-04 2021-11-26 斯特朗布里奇都柏林有限公司 用左旋酮康唑治疗疾病的方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144346A (en) 1977-01-31 1979-03-13 Janssen Pharmaceutica N.V. Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
US4503055A (en) 1979-03-26 1985-03-05 Janssen Pharmaceutica, N.V. Derivatives of [4-(piperazin-1-yl-phenyloxymethyl)-1,3-dioxolan-2-ylmethyl]-1H-imidazoles and 1H-1,2,4-triazoles
US4814333A (en) 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients
US5432176A (en) 1988-11-29 1995-07-11 The John Hopkins University Method of retarding the progression of chronic renal failure
WO1994014446A1 (en) 1992-12-22 1994-07-07 Sepracor, Inc. Methods and compositions of (+) ketoconazole for treating fungal, yeast and dermatophyte infections
WO1994014447A1 (en) * 1992-12-22 1994-07-07 Sepracor, Inc. Methods and compositions of (-) ketoconazole for treating fungal yeast and dermatophyte infections
IL109728A0 (en) 1993-05-28 1994-08-26 Pfizer Res & Dev Indoles
US5869255A (en) * 1994-02-01 1999-02-09 The Regents Of The University Of California Probes labeled with energy transfer couples dyes exemplified with DNA fragment analysis
US6642236B1 (en) * 1998-12-14 2003-11-04 Cortendo Ab Methods for prophylactic treatment of cardiovascular disease with inhibitor of cortisol synthesis
CA2196174C (en) * 1994-08-09 2005-03-01 Per Marin Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes
US5584790A (en) * 1995-09-08 1996-12-17 Beckman Instruments, Inc. Variable inclination centrifugation assembly for rapid separation of blood
JP3092947B2 (ja) 1995-12-14 2000-09-25 メルク エンド カンパニー インコーポレーテッド ゴナドトロピン放出ホルモン拮抗剤
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US5994334A (en) * 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
SE9700642D0 (sv) 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
WO1999001423A1 (en) 1997-07-01 1999-01-14 Novo Nordisk A/S Glucagon antagonists/inverse agonists
AU3033500A (en) 1999-01-15 2000-08-01 Agouron Pharmaceuticals, Inc. Non-peptide glp-1 agonists
AU3441400A (en) 1999-03-29 2000-10-16 Uutech Limited Peptide
WO2000059887A1 (en) 1999-04-02 2000-10-12 Neurogen Corporation Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
BR0010651A (pt) 1999-05-17 2002-03-19 Novo Nordisk As Composto, uso de um composto, composição farmacêutica, e, método para o tratamento e/ou prevenção de distúrbios ou de doenças mediadas por uma ação antagonìstica de glucagon
GB9915625D0 (en) 1999-07-02 1999-09-01 Cortendo Ab Method
ES2307534T3 (es) 1999-09-28 2008-12-01 Bayer Corporation Agonistas de receptores 3 (r3) del peptido activador de la adenilato ciclasa hipofisiaria (pacap) y sus metodos de uso farmacologicos.
GB0001449D0 (en) 2000-01-21 2000-03-08 Cortendo Ab Compositions
US20020055512A1 (en) * 2000-01-21 2002-05-09 Cortendo Ab. Compositions for delivery of a cortisol antagonist
EP1409512A1 (en) 2000-06-27 2004-04-21 Aventis Pharma S.A. 20-fluoro-17(20)-vinyl steroids as inhibitors of c17-20-lyase and 5-alpha reductase
GB0118300D0 (en) 2001-07-26 2001-09-19 Cortendo Ab Formulations
US20040265827A1 (en) 2001-09-21 2004-12-30 Zhimin Zhu Regulation of human steroid 5-alpha reductase
EP1465667A4 (en) * 2001-09-24 2007-06-27 Merck & Co Inc SCREENING AND SELECTION PROCEDURE FOR STATIN COMBINATIONS
JP2005528325A (ja) 2001-09-26 2005-09-22 バイエル・フアーマシユーチカルズ・コーポレーシヨン Ｃ１７，２０リアーゼ阻害剤としての置換３−ピリジルインドール類およびインダゾール類
EP1471917A1 (en) * 2002-02-07 2004-11-03 Pfizer Limited Use of pde5 inhibitors such as sildenafil in the treatment of polycystic ovary syndrome
WO2004052390A1 (en) 2002-12-11 2004-06-24 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
WO2004080414A2 (en) * 2003-03-12 2004-09-23 Mullally John P Composition and method for treating inflammations by reducing c-reactive protein
WO2005113516A1 (en) 2004-05-14 2005-12-01 Neurocrine Biosciences, Inc. Uracil-type gonadotropin-releasing hormone receptor antagonists and methods related thereto
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
US20090233843A1 (en) 2005-01-10 2009-09-17 Cortendo Invest Ab Methods and compositions for treating diabetes, metabolic syndrome and other conditions
US20070116839A1 (en) * 2005-11-23 2007-05-24 The Coca-Cola Company High-Potency Sweetener Composition With C-Reactive Protein Reducing Substance and Compositions Sweetened Therewith
AU2007204969A1 (en) * 2006-01-10 2007-07-19 Cortendo Invest Ab Methods and compositions for treating prostate cancer
AU2007303219A1 (en) 2006-10-02 2008-04-10 Cortendo Ab (Publ) Ketoconazole enantiomer in humans
JP2013540145A (ja) 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス コルチゾール依存性疾患の治療用の選択的ｃｙｐ１１ｂ１阻害剤

Also Published As

Publication number Publication date
US20100093755A1 (en) 2010-04-15
US20180125841A1 (en) 2018-05-10
EP2076265A4 (en) 2010-09-22
WO2008042898A9 (en) 2008-09-04
WO2008042898A2 (en) 2008-04-10
ZA200902127B (en) 2010-07-28
EP2076265A2 (en) 2009-07-08
AU2007303219A1 (en) 2008-04-10
RU2009116632A (ru) 2010-11-10
WO2008042898A3 (en) 2008-10-23
US20190209555A1 (en) 2019-07-11
CA2664800A1 (en) 2008-04-10
NO20091593L (no) 2009-04-22
NZ576569A (en) 2012-05-25
JP2010505866A (ja) 2010-02-25
US9198906B2 (en) 2015-12-01
IL197986A0 (en) 2009-12-24
US20160067243A1 (en) 2016-03-10

Similar Documents

Publication Publication Date Title
EP2087096A4 (en) MODIFIED CYANOBACTERIA
DE602007012130D1 (de) Modifizierte flavin-adenin-dinucleotid-abhängige glucose-dehydrogenase
CR10841A (es) Imidazotriazinas imidazopirimidinas inhibidores de cinasa
DE602007003427D1 (de) Motorrad
ITRM20070190A1 (it) Motorcycle
AT504580A3 (de) Scan-einrichtung
DE602007003411D1 (de) Motorrad
ATE546437T1 (de) Aminomethyl-4-imidazole
DE602007001442D1 (de) Motorrad
DE502007000218D1 (de) nsetzungen
DE502007000361D1 (de) Stanznieteinheit
DE602007000714D1 (de) Motorrad
DE112007003147A5 (de) Rohr-Biegevorrichtung
EP2054074A4 (en) MODIFIED ERYTHROPOIETIN
DE602007002436D1 (de) Motorrad
BRPI0719835A2 (pt) Enantiômero de cetoconazol em humanos
BRPI0719956A2 (pt) Radiofluoração
DE102006045567A8 (de) Crimpstabilisierung
DE602007011150D1 (de) Motorrad
DE112007001125A5 (de) Käfigmutter
DE502007004151D1 (de) Texturiermaschine
BRPI0712951A2 (pt) Unidade de aplicação
DE602007001380D1 (de) Motorrad
DE602007011530D1 (de) Motorrad
DE602007003264D1 (de) Scooterähnliches Motorrad

Legal Events

Date Code Title Description
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 5A, 6A E 7A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2277 DE 26/08/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A, 8A, 9A, 10A, 11A, 12A E 13A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.